Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2020
Bristol Myers Squibb completes acquisition of MyoKardia
Bristol Myers Squibb completed its $13.1 billion acquisition of MyoKardia, gaining rights to MyoKardia’s investigational treatment mavacamten and its cardiovascular drug pipeline.
2020
LianBio licenses drug programs for China and selected Asian markets
LianBio launched with three assets licensed from MyoKardia and BridgeBio Pharma companies Navire Pharma and QED Therapeutics. In exchange, LianBio agreed to pay more than $60 million upfront for development and commercialization rights in China and selected Asian markets; the article also reports a $26.5 million upfront payment for infigratinib.
2019
MyoKardia reports third-quarter 2019 financial results
MyoKardia reported financial results for the quarter ended September 30, 2019, including a net loss of $141.8 million for the quarter.